BPC-157 Protocol for Tissue Repair: A Physician’s Approach (2026)
What a performance-medicine physician actually reports doing with BPC-157 — and how it maps onto the (mostly animal) evidence.
Abstract: Most BPC-157 protocol guides recycle the same microgram number with no provenance. This one rebuilds a BPC-157 protocol for tissue repair from a single, named clinical source — Dr. Craig Koniver’s reported practice — and stress-tests every dose, route, and cycle against the underlying animal literature and the animal-to-human conversion math.
A useful BPC-157 protocol has to answer four practical questions: how much, by what route, for how long, and with what. The internet answers all four with a confident-sounding “300–500 mcg subcutaneously” and moves on. That number isn’t wrong, but it’s floating free of any reasoning — and BPC-157 is a peptide where the reasoning matters, because almost everything we “know” about it comes from rats, not people.
This guide takes a different route. It rebuilds the protocol from one named clinical source — Dr. Craig Koniver, MD, a performance-medicine physician who has discussed BPC-157 at length on the Huberman Lab podcast — and then checks his numbers against the published animal data and the animal-to-human dose conversion method. Where his clinical observation and the literature agree, you can lean on it. Where they don’t, you’ll know that too.
Provenance & framing
Dr. Koniver’s statements are clinical anecdote — observations across his practice, not controlled trials. The supporting studies cited here are overwhelmingly animal or in-vitro. Nothing below is medical advice or a dosing directive; it is a research/educational synthesis of what has been reported and used, framed so the jump from animal data to human practice is always visible. See our peptide side-effects & safety guide before considering any peptide.
Why a physician reaches for BPC-157 first
Koniver describes BPC-157 as the single most-utilized peptide in his clinic — something he’d “like to use with almost every patient.” His rationale is mechanistic and unglamorous: most adults are quietly inflamed. Aging joints stiffen, athletes carry training inflammation, and chronic disease is inflammatory at its core. Across what he reports as thousands of patients, the pattern he describes is consistent — inflammation markers come down, joints hurt less, recovery improves.
That broad anti-inflammatory action is what makes BPC-157 a tissue-repair peptide rather than a niche one. Its best-characterized mechanism is angiogenesis — the growth of new blood vessels into injured tissue — driven by nitric oxide (eNOS) and VEGF upregulation, plus fibroblast migration. In a 2011 tendon-cell study, BPC-157 promoted tendon-fibroblast outgrowth, survival under stress, and migration via the FAK–paxillin pathway, and notably increased growth-hormone-receptor expression in those cells (Chang et al., 2011). A 2006 rat study found it accelerated healing of a fully transected Achilles tendon (Staresinic et al., 2006). Where BPC-157 shines, in Koniver’s framing, is exactly there: ligaments and tendons — the muscle-to-bone junctions where strains, sprains, and tears happen, and where conventional steroid injections actively damage tissue.
For the deeper mechanism-by-injury breakdown, see our BPC-157 healing timeline by injury type and the full BPC-157 guide.
The honest evidence picture
Before any protocol, the caveat that competitor pages skip: human data on BPC-157 is thin. It amounts to roughly three tiny studies (a single-dose interstitial-cystitis study in 12 women, a 2-person IV safety report, a 16-person retrospective knee series) plus a registered oral-safety trial that was never published, and a Croatian phase-1/2 enema program for ulcerative colitis whose full data remain unpublished. Nearly all of the efficacy literature is animal, and much of it comes from a single research group (Sikiric et al., 2018; 2020; Seiwerth et al., 2018).
This is why the protocol below is built as a reasoned estimate, not a prescription — and why “start low” isn’t a throwaway line.
The BPC-157 protocol dose: where 500 mcg comes from
Koniver reports starting conservatively — ~500 mcg/day — and titrating up over time, in some cases to ~5,000 mcg/day, on a 5-days-on / 2-days-off schedule. He’s explicit that the starting point was anchored to animal studies and then dialed in clinically.
Does that survive the math? The animal-to-human conversion runs a typical rat efficacy dose (10 mcg/kg, intraperitoneal) through FDA Kₘ allometric scaling (×0.162 for rat→human) and a route adjustment (IP is ~40% more bioavailable than subcutaneous, so ×1.4), then per-body-weight. The result is a human-equivalent dose of roughly 181 mcg/day subcutaneous for an 80 kg adult. Anecdotal human ranges reported elsewhere — 250–500 mcg/day — sit just above that estimate, which is reassuring: Koniver’s conservative start is in the same order of magnitude as the modeled HED, and the climb to milligram-range doses is clinical escalation, not a first dose.
The takeaway isn’t “use 500 mcg.” It’s that a defensible BPC-157 dosage starts near the low-hundreds-of-micrograms HED and is titrated, not slammed. Other clinicians (e.g. Huberman’s solo framing) land lower and longer — ~300–500 mcg subQ, 2–3×/week — which is worth knowing as the conservative end of the same range.
Route: the counterintuitive part
Here BPC-157 breaks the rules. Most peptides are destroyed in the gut; BPC-157 is acid-resistant, so oral forms survive — and Koniver reports oral BPC localizing to the digestive tract, making it his tool for gut-driven problems (IBD, Crohn’s, ulcerative colitis, IBS, leaky gut). If your target is the gut, oral BPC capsules are the logical route — see our dedicated piece on BPC-157 for gut health.
But for musculoskeletal repair, the counterintuitive finding is that subcutaneous injection works better — even for some gut issues — and, crucially, works systemically. Koniver describes injecting into the abdomen (a tiny 30–31 gauge insulin needle) and seeing benefit in a distant joint. You do not need to inject “at the injury.” Circulation distributes it; BPC-157’s fibroblast-migration and angiogenic signaling appear to find the damaged tissue. For acute orthopedic cases he also describes injecting directly into tendons alongside PRP/PRF — something you’d never do with a corticosteroid.
So the route rule is simple: subcutaneous for systemic/musculoskeletal repair; oral (arginate salt) when the gut is the target. Injectable BPC-157 covers the first case.
Cycling: why the weekends-off matters
Koniver’s 5-on / 2-off weekly rhythm, and the broader principle of cycling rather than dosing indefinitely, reflects a recurring theme in his practice: anything you expose the body to continually becomes less potent — the same logic he applies to supplements and training. Other protocols formalize this into longer blocks — for instance 4–8 weeks on, then 4–8 weeks off, or use-until-healed-then-stop. The shared principle across all of them: BPC-157 is a targeted repair tool, not a daily forever-supplement.
That principle is also a safety one (next section).
Stacking: the growth-hormone-receptor trick
The most useful protocol insight from Koniver is a synergy most guides miss. BPC-157 upregulates the growth-hormone receptor (the Chang 2011 tendon-cell data support this mechanistically). That means it pairs unusually well with a GH-releasing peptide: you use a secretagogue like ipamorelin to push the pituitary to release more of your own GH, while BPC-157 makes the receptor bind that GH more efficiently — so you get more effect from less secretagogue.
This is the basis of the classic healing stack: BPC-157 + a GH secretagogue (ipamorelin and/or tesamorelin), often with TB-500 added for acute or major injuries, since TB-500 contributes actin-driven cell migration and structural repair on a different stage of the healing cascade. Koniver describes compounding 3–7 peptides into a single bedtime shot. For the multi-peptide rationale and how the layers complement each other, see best healing peptides 2026; a pre-paired BPC-157 + TB-500 blend exists for the acute-injury case.
Safety, sourcing & the FDA wrinkle
Two cautions are non-negotiable.
Cancer caution comes first. BPC-157 upregulates VEGF and GH receptors — the opposite of how anti-angiogenic cancer drugs work — so it could theoretically feed tumor growth or neovascular eye disease. The consistent guidance is to avoid it with any active, prior, or family-history cancer concern, to screen before use, and to keep courses short. This is the strongest argument for cycling.
Sourcing is the other. Koniver is blunt that “research use only / not for human consumption” gray-market peptides may carry LPS endotoxin, an inflammatory contaminant whose effects can be cumulative and, rarely, trigger anaphylaxis. He contrasts this with regulated compounding pharmacies, which are state Board-of-Pharmacy inspected and require outside-lab testing for purity and endotoxins. The research-grade takeaway: demand a batch-specific COA — HPLC/MS identity and purity, USP<85> endotoxin, and USP<71> sterility testing.
Finally, the regulatory wrinkle that reshaped this whole space: in October 2023 the FDA placed BPC-157 on its category-2 list, disallowing compounding. That pushed some users toward the gray market and others toward PDA (pentadeca arginate) — described as essentially the same molecule with a single amino-acid substitution (an acetate swapped for an arginate), reported as clinically “very close to BPC.” Provenance on PDA is even earlier-stage than BPC-157, so treat it as a candidate, not an equivalent.
FAQ
What is the standard BPC-157 protocol for tissue repair? The reported physician approach starts conservatively (~500 mcg/day subcutaneous, with some clinicians using 300–500 mcg 2–3×/week), titrates as needed, runs 5 days on / 2 days off, and cycles in blocks (commonly 4–8 weeks on, then off) rather than continuously. All of this is clinical anecdote plus animal-data modeling, not a validated human dose.
Should I inject BPC-157 at the site of injury? According to Koniver’s clinical observation, no — subcutaneous injection (e.g. in the abdomen) acts systemically and reaches distant injuries. Direct-to-tendon injection is reserved for specific acute orthopedic cases, often combined with PRP/PRF.
Oral or injectable BPC-157? BPC-157 is acid-resistant, so oral forms survive the gut and are favored for gut-localized issues (IBS, IBD, leaky gut). For musculoskeletal and systemic repair, subcutaneous injection is reported to work better.
How long should a BPC-157 cycle last? Protocols converge on targeted, time-limited use — weekends off weekly, and blocks of roughly 4–8 weeks before a break — rather than indefinite daily dosing. Short courses also limit the theoretical cancer/angiogenesis risk.
Is BPC-157 proven in humans? No. Human evidence is limited to a few small studies; the efficacy literature is overwhelmingly animal, much of it from one research group. Treat all protocols as research/educational estimates.
References
- Chang, C.H. et al. (2011). The promoting effect of BPC 157 on tendon healing. Journal of Applied Physiology, 110(3), 774–780. PMID 21148156. doi:10.1152/japplphysiol.00945.2010
- Staresinic, M. et al. (2006). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. Journal of Orthopaedic Research, 24(5), 1142–1148.
- Seiwerth, S. et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Current Pharmaceutical Design, 24(18), 1972–1989.
- Sikiric, P. et al. (2020). Stable gastric pentadecapeptide BPC 157-therapy for gastrointestinal tract. Current Pharmaceutical Design, 26(25), 2985–2997.
- Koniver, C. (2025). Dr. Craig Koniver on Peptides & Performance Medicine. Huberman Lab Podcast. Source
Research and educational use only. This article is not medical advice and does not recommend, prescribe, or direct the use of any peptide in humans. BPC-157 is not an FDA-approved drug; statements attributed to physicians are clinical anecdote, and the supporting evidence is largely preclinical. Consult a qualified, licensed physician before considering any compound. — Indexa Labs Research Team